Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia (CP-CML) significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment.
A race-free algorithm is merely the start for a safety net hospital confronting an onslaught of kidney disease
This is Part 6 of Embedded Bias, a series revealing how race-based clinical algorithms pervade medicine and why it’s so difficult to change them. NEW
September 10, 2024